This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through November 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised
by Zacks Equity Research
WAT beats Q3 2026 earnings and revenue estimates, fueled by acquisitions and strong organic growth and raises its full-year revenue and earnings outlook.
WATNegative Net Change MMSINegative Net Change OPKPositive Net Change GMEDNegative Net Change
earnings medical medical-devices
BDX Gears Up to Report Q4 Results: How to Play the Stock?
by Zacks Equity Research
BD heads into Q4 earnings with expectations of higher profits despite lower revenues, backed by strength in Interventional, Medical Essentials and Biologics.
BDXPositive Net Change GMEDNegative Net Change PAHCPositive Net Change GKOSNegative Net Change
medical medical-devices
RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up
by Zacks Equity Research
Revvity's Q3 2026 earnings and revenues beat estimates, fueled by Life Sciences growth and margin expansion, prompting an upward revision to its annual outlook.
RVTYNegative Net Change ISRGPositive Net Change OPKPositive Net Change GMEDNegative Net Change
earnings medical medical-devices
DexCom to Launch 15-Day G7 CGM System in Canada This November
by Zacks Equity Research
DXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.
DXCMPositive Net Change ISRGPositive Net Change OPKPositive Net Change GMEDNegative Net Change
medical medical-devices
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
by Moumi Mondal
Boston Scientific's steep valuation discount faces a major test as earnings estimates weaken, core franchises lose momentum and key growth catalysts shift to 2028.
BSXPositive Net Change ABTPositive Net Change MDTPositive Net Change
medical medical-devices
Will MCK's Pharma & Specialty Demand Offset Pricing Headwind in Q2?
by Zacks Equity Research
McKesson's Q2 earnings outlook hinges on strong prescription volumes, specialty distribution and oncology growth amid branded drug pricing pressures.
MCKPositive Net Change BDXPositive Net Change GMEDNegative Net Change GKOSNegative Net Change
medical medical-devices
Mettler-Toledo's Q3 Earnings on Deck: What's in Store for the Stock?
by Zacks Equity Research
MTD's Q3'26 results are expected to benefit from improving markets, automation demand, acquisitions and growth across key regions.
MTDPositive Net Change BDXPositive Net Change CORPositive Net Change PAHCPositive Net Change
earnings medical medical-devices
BrightSpring Q3 Earnings Beat on Specialty Growth, '26 View Raised
by Zacks Equity Research
BTSG's Q3 2026 earnings surge 80% as strong pharmacy and home health growth fuel a revenue beat, margin expansion and higher full-year guidance.
BTSGNegative Net Change ISRGPositive Net Change OPKPositive Net Change GMEDNegative Net Change
earnings medical medical-devices
BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment
by Zacks Equity Research
BDX launches its Liverty TIPS Stent Graft in the United States, offering greater precision and flexibility in portal hypertension treatment.
BDXPositive Net Change ISRGPositive Net Change OPKPositive Net Change GMEDNegative Net Change
medical medical-devices
SOLV's Q3 Earnings: Can Growth Momentum Offset ERP-Related Headwinds?
by Zacks Equity Research
Solventum's Q3 results are likely to face ERP-related order reversals and tariff pressures, while MedSurg, Dental and Acera growth may have supported underlying performance.
SOLVPositive Net Change EWPositive Net Change GMEDNegative Net Change GKOSNegative Net Change
medical medical-devices